The heme degradation enzyme biliverdin IXβ reductase (BLVRB) is implicated in a redox-regulated thrombopoietic pathway. Here, the authors validate BLVRB as a cellular target by generating an orally-available small molecule inhibitor that retains platelet-enhancing functions that are mechanistically distinct from thrombopoietin receptor-targeted mimetics.
- Natasha M. Nesbitt
- Gian Luca Araldi
- Wadie F. Bahou